Related Experiment Video
Updated: Jan 31, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance
Veenu Tripathi1, Jee-Hye Shin1, Christina H Stuelten1
1Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Abstract:
Transforming growth factor-β (TGF-β) is major inducer of epithelial-to-mesenchymal transition (EMT), which associates with cancer cell metastasis and resistance to chemotherapy and targeted drugs, through both transcriptional and non-transcriptional mechanisms. We previously reported that, in cancer cells, heightened mitogenic signaling allows TGF-β-activated Smad3 to interact with poly(RC) binding protein 1 (PCBP1) and together they regulate many alternative splicing events that favors expression of protein isoforms essential for EMT, cytoskeletal rearrangement, and adherens junction signaling. Here we show that the exclusion of TGF-β-activated kinase 1 (TAK1) variable exon 12 requires another RNA-binding protein, Fox-1 homolog 2 (Rbfox2), which binds intronic sequences in front of exon 12 independently of the Smad3-PCBP1 complex. Functionally, exon 12-excluded TAK1∆E12 and full-length TAK1FL are distinct. The short isoform TAK1∆E12 is constitutively active and supports TGF-β-induced EMT and nuclear factor kappa B (NF-κB) signaling, whereas the full-length isoform TAK1FL promotes TGF-β-induced apoptosis. These observations offer a harmonious explanation for how a single TAK1 kinase can mediate the opposing responses of cell survival and apoptosis in response to TGF-β. They also reveal a propensity of the alternatively spliced TAK1 isoform TAK1∆E12 to cause drug resistance due to its activity in supporting EMT and NF-κB survival signaling.
Insights
Transforming growth factor-β (TGF-β) induces epithelial-to-mesenchymal transition (EMT) and drug resistance. We found a novel mechanism involving RNA-binding proteins that controls TGF-β-activated kinase 1 (TAK1) splicing, impacting cancer cell survival and apoptosis.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Transforming growth factor-β (TGF-β) is a key regulator of epithelial-to-mesenchymal transition (EMT), a process linked to cancer metastasis and therapeutic resistance.
- Previous work identified Smad3 and PCBP1 complex regulating alternative splicing in response to TGF-β, favoring EMT-associated isoforms.
- The distinct roles of TGF-β-activated kinase 1 (TAK1) isoforms in cellular responses remain incompletely understood.
Purpose of the Study:
- To elucidate the mechanism controlling the alternative splicing of TAK1 in response to TGF-β.
- To characterize the distinct functions of TAK1 isoforms generated by alternative splicing.
- To understand the contribution of TAK1 splicing to TGF-β-mediated cellular outcomes, including EMT and drug resistance.
Main Methods:
- RNA-binding protein immunoprecipitation (RIP).
- Analysis of alternative splicing events using molecular biology techniques.
- Functional assays assessing cell signaling pathways (EMT, NF-κB) and apoptosis.
- Western blotting to detect protein isoforms.
Main Results:
- The RNA-binding protein Rbfox2 mediates the exclusion of TGF-β-activated kinase 1 (TAK1) exon 12, independent of the Smad3-PCBP1 complex.
- The alternatively spliced TAK1 isoform lacking exon 12 (TAK1∆E12) is constitutively active and promotes TGF-β-induced EMT and nuclear factor kappa B (NF-κB) signaling.
- The full-length TAK1 isoform (TAK1FL) promotes TGF-β-induced apoptosis, while TAK1∆E12 confers resistance to chemotherapy and targeted drugs by supporting EMT and NF-κB survival signaling.
Conclusions:
- A novel splicing mechanism involving Rbfox2 controls TAK1 isoform expression in response to TGF-β.
- Distinct TAK1 isoforms mediate opposing cellular responses: TAK1∆E12 promotes survival and EMT, while TAK1FL promotes apoptosis.
- The alternatively spliced TAK1∆E12 isoform is a potential driver of drug resistance in cancer through its pro-EMT and pro-survival signaling activities.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
TGF - β Signaling Pathway
RNA Splicing
In Vitro Drug Dissolution: Alternative Methods
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....

